Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, outlines how Boehringer Ingelheim is positioning its ...
RayThera contributes multiple undisclosed-mechanism small-molecule immunology candidates positioned for broad applicability across immune-mediated indications, expanding modality diversity beyond ...
As Connecticut moves to rein in private equity's playbook in hospital deals, pharma and life sciences leaders face a parallel ...
In today's Pharmaceutical Executive Daily, FDA staff release briefing documents flagging evidence gaps in Moderna's mRNA flu ...
Strategic emphasis has shifted away from Novavax-led commercialization toward enabling partners with global scale, exemplified by Sanofi’s worldwide rights to market the COVID vaccine and Pfizer’s ...
Silvia Taylor of Novavax details how the company leverages its expertise in vaccine development to build partnerships across ...
Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, explains why shifting the conversation from simple ...
Kardigan’s offering proposes 23.3 million shares at $14–$16, targeting ~$350 million gross proceeds and an implied ~$1.3 ...
Phase III P304 (n=40,805) showed 26.6% relative efficacy versus standard-dose influenza vaccine for RT-PCR-confirmed influenza-like illness, increasing to 47.9% when anchored to higher-acuity ...
FDA approved Skinvive by Juvéderm to reduce neck lines and improve neck appearance in adults over the age of 21. The approval marks the first and only hyaluronic acid injectable ...
In January of this year, Novavax announced a partnership that would provide its Matrix-M adjuvant technology to Pfizer for ...
Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, argues the field must evolve beyond the scale, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results